Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
7.25
+0.07 (0.97%)
At close: Mar 9, 2026, 4:00 PM EDT
7.25
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:01 PM EDT
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $347.75 million as of March 9, 2026. Its market cap has increased by 259.24% in one year.
Market Cap
347.75M
Enterprise Value
186.68M
1-Year Change
259.24%
Ranking
Category
Stock Price
$7.25
Market Cap Chart
Since August 10, 2021, Climb Bio's market cap has decreased from $403.20M to $347.75M, a decrease of -13.75%. That is a compound annual growth rate of -3.18%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 342.97M | 79.59% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Candel Therapeutics | 361.84M |
| Bicycle Therapeutics | 360.71M |
| Absci | 357.88M |
| Aura Biosciences | 355.62M |
| Immuneering | 344.16M |
| Neurogene | 343.41M |
| Foghorn Therapeutics | 338.60M |
| Opus Genetics | 337.23M |